TrialBMC medicine2025

Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial.

Lilan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.